SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021

Katsutoshi Nagano[a,†], Chihiro Tani-Sassa[a,†], Yumi Iwasaki[a], Yuna Takatsuki[a], Sonoka Yuasa[a], Yuta Takahashi[a], Jun Nakajima[a], Kazunari Sonobe[a], Naoya Ichimura[a], Yoko Nukui[b], Hiroaki Takeuchi[c], Kousuke Tanimoto[d,e], Yukie Tanaka[e], Akinori Kimura[f], and Shuji Tohda[a,*]

[a] Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

[b] Infection Control and Prevention, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan

[c] Department of Molecular Virology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

[d] Genome Laboratory, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

[e] Institute of Research, Research Core, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

[f] Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

[†]These authors contributed equally

[*] Corresponding author: Shuji Tohda, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

E-mail address: tohda.mlab@tmd.ac.jp

Abstract

Background: The spread of SARS-CoV-2 variants, such as B.1.1.7 and B.1.351, has become a crucial issue worldwide. Therefore, we began testing all patients with COVID-19 for the N501Y and E484K mutations associated with SARS-CoV-2.

Study design: Nasopharyngeal swab samples from 108 patients who visited our hospital between February and April 2021 were analyzed. The samples were analyzed using reverse transcription-polymerase chain reaction with melting curve analysis to detect the N501Y and E484K mutations. A part of the samples were also subjected to whole genome sequencing. Clinical parameters such as mortality and admission to the intensive care unit were analyzed to examine the association between increased disease severity and the E484K mutation.

Results: The ratio of cases showing the 501N+484K mutation rapidly increased from 8% in February to 46% in March. Whole genome sequencing revealed that the viruses with 501N+484K mutation are R.1 lineage variants. Evidence of increased disease severity related to the R.1 variants were not found.

Conclusions: We found that the R.1 lineage variants rapidly prevailed in Tokyo in March 2021.

Keywords: SARS-CoV-2, COVID-19, E484K variant, R.1 lineage, PCR, Melting curve analysis

1. introduction

Since the beginning of 2021, the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants such as B.1.1.7 (United Kingdom type), B.1.351 (South Africa type), and P.1 (Brazil type) has become a crucial issue worldwide [1-4]. We are also aware of this issue at our hospital, Tokyo Medical and Dental University Hospital, which mainly treats patients with severe coronavirus disease 2019 (COVID-19) in Tokyo.

Therefore, we began testing all samples from outpatients and inpatients who tested polymerase chain reaction (PCR)-positive for SARS-CoV-2 for its associated mutations, N501Y and E484K, using PCR-based melting curve analysis. We found that the conventional strains (European lineage) with the 501N+484E which accounted for the majority of cases until February were replaced by R.1 variants with 501N+484K mutation in March. Since studies of the R.1 variants have rarely been reported, here we present the findings from patients with COVID-19 treated at our hospital.

2. Material and methods

This study included 108 patients with COVID-19 who visited our hospital from February to April 2021. The nasopharyngeal swab samples obtained from patients were immersed in test tubes with 1 mL of phosphate-buffered saline containing 1% dithiothreitol. To detect SARS-CoV-2 in the samples, one-step reverse transcription-quantitative PCR (RT-qPCR) was performed without viral RNA purification using the 2019 Novel Coronavirus Detection Kit (Shimadzu Corp.; Kyoto, Japan) and the

QuantStudio 5 Dx Real-Time PCR System (Thermo Fisher Scientific, Inc.; Waltham, MA, USA).

To detect N501Y and E484K mutations, viral RNA was purified from the PCR-positive samples using the EZ1 Virus Mini Kit v2.0 and EZ1 advanced XL (QIAGEN; Venlo, Netherlands). RT-PCR was performed using the primers and probes provided in the VirSNiP SARS-CoV-2 Spike N501Y and VirSNiP SARS-CoV-2 Spike E484K kits (TIB Molbiol; Berlin, Germany) and the LightCycler Multiplex RNA Virus Master (Roche Molecular Systems, Inc.; Basel, Switzerland). The Melting curve analyses of the PCR products were performed according to the manufacturer's instructions, and the 501N, 501Y, 484E, and 484K types were determined by the melting temperature.

Using a part of the samples that showed 501N+484E, 501N+484K, and 501Y+484E, whole genome sequencing (WGS) was performed using a next-generation sequencer to specify the lineages.

To investigate whether the 501N+484K variants are involved in the increased severity of the disease, we compared elements from the patients' clinical profiles, such as mortality and admission to the intensive care unit (ICU), between 501N+484E and 501N+484K patients who were discharged by April 30.

This study was approved by Medical Research Ethics Committee of Tokyo Medical and Dental University (approval number: M2020-004) and was conducted in accordance with the ethical standards of the 1964 Helsinki declaration.

3. Results

The number of cases by the three variant types in each month is shown in Figure 1. Samples for which the 501 or 484 type could not be determined were classified as

untyped. In February, the 501N+484E type accounted for 80% of cases and the 501N+484K type for 8%. In March, the 501N+484K type increased to 46% and the 501Y+484E type appeared at the end of March. In April, along with the rapid increase of patients with COVID-19, the 501Y+484E variant type increased and accounted for about half of all cases. The variant type of 501Y+484K, which corresponds to the B.1.351 and P.1 variants, were not found during the three-month study period.



Figure 1. Number of cases by each variant type determined by PCR-based melting curve analysis

Figure 2 shows the distribution of the copy numbers from the samples showing 501N, 501Y, 484E, and 484K and samples that did not produce enough PCR products for melting curve analysis and the typing. There were no significant differences in the copy numbers between the 501N and 501Y samples or between the 484E and 484K samples. This figure suggests that the 501 and 484 types may

not be determined if the viral RNA concentration in swab-soaked samples is approximately less than 100 copies/μL or less than 1,000 copies/μL, respectively.



Figure 2. Distribution of viral RNA copy numbers of in swab-soaked samples showing 501N, 501Y, 484E, 484K types and samples which could not be determined. ND, not determined.

WGS analysis of the selected samples revealed that the 501N+484K type is an R.1 lineage (W152L, E484K, D614G, G769V) variant, which is derived from the B.1.1.316 lineage. The 501Y+484E variant type is from the B.1.1.7 lineage (United Kingdom lineage) and the 501N+484E type is from the B.1.1.214 lineage (Japan lineage).

Table 1 shows the clinical profiles of 501N+484E (n=25) and 501N+484K (n=20) cases. There were no significant differences in any of the variables between the two groups. The length of hospitalization tended to be short in the 501N+484K group, since this group included four patients who did not need hospitalization.

Table 1

Clinical parameters of cases showing 501N+484E and 501N+484K types

	501N+484E (n=25)	501N+484K (n=20)
Age (years) mean (standard deviation)	68.3 (12.8)	66.1 (21.2)
Male ratio (%)	68	50
Mortality rate (%)	12	20
Cases treated at the ICU (%)	36	25
Hospitalization (days) mean (standard deviation)	21 (15)	14 (10)
median (range)	18 (1 - 65)	13 (0 - 32)

4. Discussion

The B.1.1.7 variant is known to have high transmissibility [1] and mortality [2]. However, there are few reports about R.1 lineage. R.1 variants have also been detected in the United States and Europe according to the PANGO lineage database [5]. However, the spread of R.1 variants during the pandemic in a particular area has not been reported.

In this study, we have found that the R.1 lineage variants rapidly prevailed in Tokyo in March 2021. The limitation of our study is that the target is limited to the patients who visited our hospital. However, we believe this finding also applies to Tokyo as a whole because the prevalence of R.1 variants in March was not only seen in our hospital, but also in a random sampling survey of patients in Tokyo recently performed by the Tokyo Metropolitan Institute of Public Health [6].

Regarding the transmissibility of the R.1 variants, the fact that they rapidly replaced the B.1.1.214 variants in March suggests increased infectivity. Because there were

already many patients with COVID-19 in Tokyo in February, the founder effect of the R.1 variants seems unlikely. In contrast, R.1 variants were rapidly replaced by B.1.1.7 variants in April. This suggests that the B.1.1.7 variants have stronger infectivity, as previously reported [1].

Regarding the severity of R.1 variants, there was no significant difference in mortality, ICU admission, and length of hospitalization between R.1 and B.1.1.214 cases, although the number of cases was small to be concluded. Our results suggest that the R.1 variants are not involved in the increased severity of the disease.

The E484K mutation has been reported to cause immune escape [7]. The preventive effects of antibodies produced by vaccination can be diminished by E484K mutations. In fact, outbreaks of R.1 variants in a nursing facility that occurred after the residents and personnel were vaccinated were reported, although the infection rate of the vaccinated people was significantly lower than that of unvaccinated people [8].

We think the testing for detection of the E484K mutation and surveillance of the R.1 variant distributions are important for SARS-CoV-2 infection control.

Acknowledgments

We would like to thank all the staff involved in COVID-19 treatment that led to this study.

Author contributions

Conceived and designed the study: KN, CTS, NI, YN, HT, ST. Analyzed samples: KN, CTS, YI, YT, SY, YT, JN, KS. Performed WGS: HT, KT, YT, AK. Analyzed data: NI, ST. Wrote the paper: ST.

Funding information

WGS was supported by: grant JPMJCR20H2 from JST-CREST; grant 20nk0101612h0901 from Japan Agency for Medical Research and Development.

Declaration of Competing Interest

The authors declare no conflicts of interests.

References

[1] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP; COVID-19 Genomics UK (COG-UK) consortium, Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021. doi: 10.1038/s41586-021-03470-x. Epub ahead of print.

[2] Davies NG, Jarvis CI; CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021. doi: 10.1038/s41586-021-03426-1. Epub ahead of print.

[3] Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, Giandhari J, Pillay S, Wilkinson E, Naidoo Y, Karim F, Ganga Y, Khan K, Bernstein M, Balazs AB, Gosnell BI, Hanekom W, Moosa MS; Network for Genomic Surveillance in South Africa; COMMIT-KZN Team, Lessells RJ, de Oliveira T, Sigal A. Escape of SARS-CoV-2

501Y.V2 from neutralization by convalescent plasma. Nature. 2021. doi: 10.1038/s41586-021-03471-w. Epub ahead of print.

[4] Martins AF, Zavascki AP, Wink PL, Volpato FCZ, Monteiro FL, Rosset C, De-Paris F, Ramos ÁK, Barth AL. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. Euro Surveill. 2021 Mar;26(12):2100276. doi: 10.2807/1560-7917.ES.2021.26.12.2100276.

[5] PANGO lineages database. Available at https://cov-lineages.org/lineages/lineage_R.1.html. Accessed May 1.

[6] Tokyo Metropolitan Institute of Public Health. Available at http://www.tokyo-eiken.go.jp/lb_virus/sars2ngstree/. Accessed May 1.

[7] Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184: 2372-2383.e9. doi: 10.1016/j.cell.2021.03.013.

[8] Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, Tobias J, Lunn S, Miller T, Thoroughman D, Spicer KB. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. MMWR Morb Mortal Wkly Rep. 2021;70: 639-643. doi: 10.15585/mmwr.mm7017e2.